Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis
Ovarian cancer (OC) is prone to peritoneum or omentum dissemination, thus giving rise to the formidable challenge of unresectable surgery and a dismal survival rate. Although niraparib holds a pivotal role in the maintenance treatment of OC, its effect on suppressing metastases during primary interv...
Saved in:
| Main Authors: | Ning Jin, Yi-yu Qian, Xiao-fei Jiao, Zhen Wang, Xin Li, Wen Pan, Jin-kai Jiang, Pu Huang, Si-yuan Wang, Ping Jin, Qing-lei Gao, Dan Liu, Yu Xia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Redox Biology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231725000412 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review
by: Gonzalez A, et al.
Published: (2024-12-01) -
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
by: Whitney S Graybill, et al.
Published: (2024-12-01) -
Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01) -
Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01) -
Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study
by: Deng T, et al.
Published: (2025-07-01)